



Republic of the Philippines
Department of Health
FOOD AND DRUG ADMINISTRATION



FDA ADVISORY
No. **2020-1986**

30 OCT 2020

TO: ALL HEALTHCARE PROFESSIONALS AND THE GENERAL PUBLIC

SUBJECT: Safety Communication: Updates on Influenza Vaccine

The Food and Drug Administration (FDA) would like to update all healthcare professionals and the general public regarding Korea's reported deaths following influenza immunization and supplies of influenza vaccine in the Philippines.

As a precautionary measure, the FDA investigated if the same products used in Korea were brought into the Philippines. None of the products used in Korea were imported in the country for use in influenza vaccination.

The FDA searched the national database of adverse reactions, there were no reports of life-threatening adverse events received on the use of the influenza vaccine of any brand to date. Several mild adverse reactions including pain in the injection site, pruritus, and fever have been reported.

The FDA strongly recommends immunization against influenza; healthcare professionals are advised to take caution on the medical conditions of the patients prior to administration and discuss possible side effects.

All are enjoined to report side effects (adverse events following immunization) to FDA through this link: <https://primaryreporting.who-umc.org/Reporting/reporter?OrganizationID=PH> and fill out all the required fields. For other inquiries, email us at pharmacovigilance@fda.gov.ph.


ROLANDO ENRIQUE D. DOMINGO, MD
Director General



20201028144139

